PfSPZ Challenge (for CHMI)

BIOLOGICAL3 trials

Sponsors

Sanaria Inc.

Conditions

Malaria

Phase 1

Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants

CompletedNCT02613520

Sanaria Inc.Malaria

Start: 2015-12-31End: 2017-03-31Updated: 2018-10-15

Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea.

CompletedNCT02859350

Sanaria Inc.Malaria

Start: 2016-11-30End: 2018-02-28Updated: 2018-10-15

Regimen Optimization Trial of PfSPZ Vaccine in Equatorial Guinea

CompletedNCT03590340

Sanaria Inc.Malaria

Start: 2018-07-30End: 2019-03-12Updated: 2020-01-07

Related Papers

Diagnostic performance and comparison of ultrasensitive and conventional rapid diagnostic test, thick blood smear and quantitative PCR for detection of low-density Plasmodium falciparum infections during a controlled human malaria infection study in Equatorial Guinea.

2022-03-2417 citations

Increase of Dose Associated With Decrease in Protection Against Controlled Human Malaria Infection by PfSPZ Vaccine in Tanzanian Adults

Clinical Infectious Diseases2019-11-2870 citations

Two cases of long-lasting, sub-microscopic Plasmodium malariae infections in adults from coastal Tanzania

Malaria Journal2019-04-297 citations

Controlled Human Malaria Infection in Semi-Immune Kenyan Adults (CHMI-SIKA): a study protocol to investigate <i>in vivo Plasmodium falciparum</i> malaria parasite growth in the context of pre-existing immunity.

2018-01-0134 citations